Prakash S Masan

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint Atypical antipsychotics in the treatment of affective symptoms: a review
    Prakash S Masan
    Department of Psychiatry, Duke University Medical Center, Durham, North Carolina 27702 3319, USA
    Ann Clin Psychiatry 16:3-13. 2004
  2. ncbi request reprint Long-acting injectable antipsychotics in the elderly: guidelines for effective use
    Prakash S Masand
    Program for Continuing Medical Education, Department of Psychiatry, Duke University Medical Center, Durham, North Carolina 27710, USA
    Drugs Aging 20:1099-110. 2003
  3. ncbi request reprint Tolerability and adherence issues in antidepressant therapy
    Prakash S Masand
    Program for Continuing Medical Education, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Ther 25:2289-304. 2003
  4. ncbi request reprint The safety of SSRIs in generalised anxiety disorder: any reason to be anxious?
    Prakash S Masand
    Program for Continuing Medical Education, Department of Psychiatry, Box 3391, Duke University Medical Center, Durham, NC 27710, USA
    Expert Opin Drug Saf 2:485-93. 2003
  5. ncbi request reprint Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine
    Prakash S Masand
    Department of Psychiatry, Duke University Medical Center, Durham, North Carolina 27710, USA
    Ann Clin Psychiatry 14:175-82. 2002
  6. ncbi request reprint Does a preexisting anxiety disorder predict response to paroxetine in irritable bowel syndrome?
    Prakash S Masand
    Department of Psychiatry, Duke University Medical Center, Durham, NC 27710, USA
    Psychosomatics 43:451-5. 2002
  7. ncbi request reprint Prescribing conventional antipsychotics in the era of novel antipsychotics: informed consent issues
    Prakash S Masand
    Duke University Medical Center, Department of Psychiatry, Durham, North Carolina, USA
    Am J Ther 9:484-7. 2002
  8. doi request reprint History of depressive and/or anxiety disorders as a predictor of treatment response: a post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release in patients with fibromyalgia
    Chi Un Pae
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina 27704, USA
    Prog Neuropsychopharmacol Biol Psychiatry 33:996-1002. 2009
  9. doi request reprint History of early abuse as a predictor of treatment response in patients with fibromyalgia: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release
    Chi Un Pae
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA
    World J Biol Psychiatry 10:435-41. 2009
  10. doi request reprint Methylphenidate extended release (OROS MPH) for the treatment of antidepressant-related sexual dysfunction in patients with treatment-resistant depression: results from a 4-week, double-blind, placebo-controlled trial
    Chi Un Pae
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Duke Clinical Research Institute, Durham, NC 27705, USA
    Clin Neuropharmacol 32:85-8. 2009

Detail Information

Publications30

  1. ncbi request reprint Atypical antipsychotics in the treatment of affective symptoms: a review
    Prakash S Masan
    Department of Psychiatry, Duke University Medical Center, Durham, North Carolina 27702 3319, USA
    Ann Clin Psychiatry 16:3-13. 2004
    ....
  2. ncbi request reprint Long-acting injectable antipsychotics in the elderly: guidelines for effective use
    Prakash S Masand
    Program for Continuing Medical Education, Department of Psychiatry, Duke University Medical Center, Durham, North Carolina 27710, USA
    Drugs Aging 20:1099-110. 2003
    ..The choice of which drug to use should be based on patients' history of response and personal preference, clinician's previous experience and pharmacokinetic properties...
  3. ncbi request reprint Tolerability and adherence issues in antidepressant therapy
    Prakash S Masand
    Program for Continuing Medical Education, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Ther 25:2289-304. 2003
    ....
  4. ncbi request reprint The safety of SSRIs in generalised anxiety disorder: any reason to be anxious?
    Prakash S Masand
    Program for Continuing Medical Education, Department of Psychiatry, Box 3391, Duke University Medical Center, Durham, NC 27710, USA
    Expert Opin Drug Saf 2:485-93. 2003
    ..For both paroxetine and venlafaxine, the safety and tolerability profiles during treatment of GAD are consistent with those demonstrated during the short- and long-term treatment of patients with major depressive disorder...
  5. ncbi request reprint Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine
    Prakash S Masand
    Department of Psychiatry, Duke University Medical Center, Durham, North Carolina 27710, USA
    Ann Clin Psychiatry 14:175-82. 2002
    ..It may be possible to prevent discontinuation symptoms with a cross taper to another antidepressant or by slowly tapering the antidepressant...
  6. ncbi request reprint Does a preexisting anxiety disorder predict response to paroxetine in irritable bowel syndrome?
    Prakash S Masand
    Department of Psychiatry, Duke University Medical Center, Durham, NC 27710, USA
    Psychosomatics 43:451-5. 2002
    ..Both groups had similar improvement in abdominal pain, constipation, diarrhea, incomplete emptying, and bloating/ abdominal distension. Paroxetine was very well tolerated...
  7. ncbi request reprint Prescribing conventional antipsychotics in the era of novel antipsychotics: informed consent issues
    Prakash S Masand
    Duke University Medical Center, Department of Psychiatry, Durham, North Carolina, USA
    Am J Ther 9:484-7. 2002
    ..066, df = 2, Pearson chi(2) test). For patients who are receiving any antipsychotic therapy, discussions about the risks/benefits of treatments are integral for optimal treatment and medicolegal purposes...
  8. doi request reprint History of depressive and/or anxiety disorders as a predictor of treatment response: a post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release in patients with fibromyalgia
    Chi Un Pae
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina 27704, USA
    Prog Neuropsychopharmacol Biol Psychiatry 33:996-1002. 2009
    ..We investigated whether a history of depressive and/or anxiety disorders was associated with response to paroxetine controlled release (CR) in the treatment of fibromyalgia...
  9. doi request reprint History of early abuse as a predictor of treatment response in patients with fibromyalgia: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release
    Chi Un Pae
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA
    World J Biol Psychiatry 10:435-41. 2009
    ....
  10. doi request reprint Methylphenidate extended release (OROS MPH) for the treatment of antidepressant-related sexual dysfunction in patients with treatment-resistant depression: results from a 4-week, double-blind, placebo-controlled trial
    Chi Un Pae
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Duke Clinical Research Institute, Durham, NC 27705, USA
    Clin Neuropharmacol 32:85-8. 2009
    ..Adequately powered controlled trials are needed to fully evaluate the efficacy of OROS MPH in this area...
  11. ncbi request reprint Transdermal selegiline: the new generation of monoamine oxidase inhibitors
    Ashwin A Patkar
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27704, USA
    CNS Spectr 11:363-75. 2006
    ..However, more research is needed. Clinicians should familiarize themselves with the properties and indications for the new generation of MAOIs...
  12. ncbi request reprint Long-acting injectable naltrexone for the treatment of alcohol dependence
    Paolo Mannelli
    Duke University Medical Center, 2218 Elder Street, Suite 123, Durham, NC 27705, USA
    Expert Rev Neurother 7:1265-77. 2007
    ..The clinical availability of extended-release naltrexone has the potential to enhance treatment outcomes for alcohol and other drug dependence disorders...
  13. ncbi request reprint Clinical variables associated with early administration of antipsychotics in bipolar mania
    Chi Un Pae
    Department of Psychiatry, Kangnam St Mary s Hospital, The Catholic University of Korea College of Medicine, 505 Banpo Dong, Seocho Gu, Seoul 137 701, Republic of Korea
    Prog Neuropsychopharmacol Biol Psychiatry 30:151-4. 2006
    ..0 and 13.1, respectively). This study suggests that some clinical factors in bipolar mania might be linked to the earlier antipsychotic treatment. However, more studies will be needed to confirm this finding...
  14. ncbi request reprint A randomized, controlled, trial of controlled release paroxetine in fibromyalgia
    Ashwin A Patkar
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27704, USA
    Am J Med 120:448-54. 2007
    ..We investigated the efficacy and tolerability of paroxetine controlled release, a selective serotonin reuptake inhibitor in fibromyalgia...
  15. ncbi request reprint Differential pharmacology of atypical antipsychotics: clinical implications
    Prakash S Masand
    Duke University Medical Center, Durham, NC 27710, USA
    Am J Health Syst Pharm 64:S3-8; quiz S24-5. 2007
    ..Pharmacology of atypical antipsychotics and the clinical implications are reviewed...
  16. ncbi request reprint A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression
    Ashwin A Patkar
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27704, USA
    J Clin Psychopharmacol 26:653-6. 2006
    ..Combination of methylphenidate with antidepressants was well tolerated. Adequately powered, randomized, controlled trials are necessary to fully evaluate the efficacy of extended-release methylphenidate in TRD...
  17. ncbi request reprint Paroxetine: safety and tolerability issues
    David M Marks
    Duke University Medical Center, Department of Psychiatry and Behavioural Sciences, 2218 Elder Street, Durham 27705, USA
    Expert Opin Drug Saf 7:783-94. 2008
    ....
  18. doi request reprint A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome
    Prakash S Masand
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, 1001 Winstead Dr, Suite 200, Cary, NC 27513, USA
    Psychosomatics 50:78-86. 2009
    ..Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) disease that causes significant impairment in quality of life and accounts for $8 billion per year to the healthcare system and loss of productivity in the workplace...
  19. ncbi request reprint Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization
    Prakash S Masand
    Department of Psychiatry, Duke University Medical Center, Durham, North Carolina, USA
    CNS Spectr 10:suppl14 1-15. 2005
    ....
  20. ncbi request reprint Pharmacotherapy of depression in pregnancy
    Ashwin A Patkar
    Department of Psychiatry, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Ann Clin Psychiatry 16:87-100. 2004
    ..We review the safety profiles of commonly used antidepressants, discuss clinical decision making based on risk-benefit considerations and make recommendations for pharmacological treatment of depressed women during pregnancy...
  21. ncbi request reprint Comorbidity of irritable bowel syndrome in psychiatric patients: a review
    Amir Garakani
    Department of Psychiatry, Mt Sinai School of Medicine, New York, NY, USA
    Am J Ther 10:61-7. 2003
    ..Our article reviews the comorbidity of IBS in psychiatric patients and discusses implications for treatment...
  22. ncbi request reprint Improving adherence to antipsychotic pharmacotherapy
    Prakash S Masand
    Department of Psychiatry, Duke University Medical Center, Durham, North Carolina, USA
    Curr Clin Pharmacol 1:47-56. 2006
    ..To review the consequences of nonadherence to antipsychotic pharmacotherapy in patients with schizophrenia, as well as associated risk factors for nonadherence and methods of improving adherence...
  23. ncbi request reprint Prevalence of irritable bowel syndrome in obsessive-compulsive disorder
    Prakash S Masand
    Department of Psychiatry, Duke University Medical Center, Durham, NC 27705, USA
    CNS Spectr 11:21-5. 2006
    ..Irritable bowel syndrome (IBS) occurs more frequently in psychiatric patients, especially those with anxiety and mood disorders...
  24. ncbi request reprint Management of fibromyalgia
    Ashwin A Patkar
    Department of Psychiatry, Thomas Jefferson University, 833 Chestnut Street, Suite 210E, Philadelphia, PA 19107, USA
    Curr Psychiatry Rep 5:218-24. 2003
    ..Patience and positive attitude on part of the physician and active involvement of patients and their families in treatment are likely to enhance improvement...
  25. ncbi request reprint The role of atypical antipsychotics in the treatment of delirium
    Thomas L Schwartz
    Department of Psychiatry, S U N Y Upstate Medical University, Syracuse 13210, USA
    Psychosomatics 43:171-4. 2002
    ..g., schizophrenia or bipolar disorder), but few studies have evaluated them in the treatment of delirium. This paper reviews the pertinent literature and summarizes tentative guidelines for novel antipsychotic use in delirium...
  26. ncbi request reprint Second-generation antipsychotics and the metabolic syndrome
    Prakash S Masand
    Duke University Medical Center, 110 Swift Avenue, Suite 1, Durham, NC 27705, USA
    Curr Psychiatry Rep 7:153-4. 2005
  27. pmc The impact of the CONSORT statement on reporting of randomized clinical trials in psychiatry
    Changsu Han
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center and Duke Clinical Research Institute, Durham, NC, USA
    Contemp Clin Trials 30:116-22. 2009
    ..Although the overall quality of reporting on psychiatric RCTs generally improved after publication of the CONSORT statement, reporting the details of randomization, blinding, and obtaining informed consent remain insufficient...
  28. ncbi request reprint Weight decline in patients switching from olanzapine to quetiapine
    Sanjay Gupta
    Department of Psychiatry, University of Buffalo, School of Medicine and Biomedical Sciences, Buffalo, NY, USA
    Schizophr Res 70:57-62. 2004
    ..Prospective controlled trials of longer duration and larger number of subjects are needed...
  29. ncbi request reprint Use of atypical antipsychotics in a Veterans Affairs hospital
    Thomas L Schwartz
    Department of Psychiatry, SUNY Upstate Medical University, New York, USA
    Prog Neuropsychopharmacol Biol Psychiatry 26:1207-10. 2002
    ....
  30. ncbi request reprint Safety considerations in pharmacotherapy of bipolar disorder
    Prakash S Masand
    Department of Psychiatry, Duke University Medical Center, 110 Swift Ave, Suite 1, Durham, NC 27705, USA
    CNS Spectr 9:16-26. 2004
    ..More research is needed to understand potential risks of various drugs and to devise and incorporate monitoring protocols in the treatment regimen...